- Home
- WWW vs VRDN Comparison
WWW vs VRDN Comparison
Compare WWW & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWW
- VRDN
- Stock Information
- Founded
- WWW 1883
- VRDN 2006
- Country
- WWW United States
- VRDN United States
- Employees
- WWW N/A
- VRDN N/A
- Industry
- WWW Shoe Manufacturing
- VRDN Medical Specialities
- Sector
- WWW Consumer Discretionary
- VRDN Health Care
- Exchange
- WWW Nasdaq
- VRDN Nasdaq
- Market Cap
- WWW 1.0B
- VRDN 1.6B
- IPO Year
- WWW N/A
- VRDN N/A
- Fundamental
- Price
- WWW $16.33
- VRDN $12.78
- Analyst Decision
- WWW Strong Buy
- VRDN Buy
- Analyst Count
- WWW 8
- VRDN 14
- Target Price
- WWW $18.00
- VRDN $36.82
- AVG Volume (30 Days)
- WWW 1.6M
- VRDN 912.1K
- Earning Date
- WWW 05-08-2025
- VRDN 05-06-2025
- Dividend Yield
- WWW 2.45%
- VRDN N/A
- EPS Growth
- WWW N/A
- VRDN N/A
- EPS
- WWW 0.90
- VRDN N/A
- Revenue
- WWW $1,772,400,000.00
- VRDN $302,000.00
- Revenue This Year
- WWW $4.39
- VRDN N/A
- Revenue Next Year
- WWW $5.29
- VRDN $20,553.29
- P/E Ratio
- WWW $18.22
- VRDN N/A
- Revenue Growth
- WWW N/A
- VRDN 4.86
- 52 Week Low
- WWW $9.58
- VRDN $9.90
- 52 Week High
- WWW $24.64
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- WWW 72.79
- VRDN 45.25
- Support Level
- WWW $14.06
- VRDN $11.76
- Resistance Level
- WWW $14.56
- VRDN $13.99
- Average True Range (ATR)
- WWW 0.62
- VRDN 0.76
- MACD
- WWW 0.49
- VRDN -0.00
- Stochastic Oscillator
- WWW 95.55
- VRDN 35.79
About WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.